Connecticut-based medical device company, BioSig Technologies, Inc. recently announced the commercialization of an advanced digital signal processing technology platform for the effective treatment of cardiovascular arrhythmias, alongside its subsidiaries. The company's PURE EP system utilizes a signal processing platform that combines hardware and software to overcome known signal acquisition challenges. By enabling electrophysiologists to view real-time signals and analyze them, the device is designed to address the longstanding limitations that have previously disrupted cardiac catheter ablation procedures. BioSig Technologies is focused on enhancing intracardiac signal acquisition and diagnostic information for catheter ablation procedures used in the treatment of arrhythmias. The company has entered into a research partnership with the University of Minnesota to develop novel therapies for sympathetic nervous system diseases. It has also formed a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI and machine learning software solution for PURE EP systems. The company was founded in 2009 and has its headquarters in Westport, Connecticut.
BioSig Technologies, Inc.'s ticker is BSGM
The company's shares trade on the NASDAQ stock exchange
They are based in Westport, Connecticut
There are 11-50 employees working at BioSig Technologies, Inc.
It is https://www.biosig.com/
BioSig Technologies, Inc. is in the Healthcare sector
BioSig Technologies, Inc. is in the Medical Appliances & Equipment industry
The following five companies are BioSig Technologies, Inc.'s industry peers: